
Third-quarter sales and earnings beat analyst estimates as Mounjaro revenue climbed and the company lifted its full-year sales forecast.
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion and earnings per share of $7.48, beating analyst consensus estimates of $6.61 per share. The company raised its full-year revenue outlook.
Mounjaro generated $10.723 billion in sales during the quarter, up 65% from a year earlier. The drug is used to treat Type 2 diabetes and obesity. Eli Lilly also cited continued global demand for diabetes and obesity treatments.
The company now expects 2026 revenue of $91 billion to $92 billion, up from its previous forecast of $85 billion to $87 billion. The new range is above the $88.74 billion analyst consensus cited in the report.
Eli Lilly slightly lowered its adjusted earnings-per-share forecast to $35 to $36. The company cited $4.57 per share in charges related to acquired research and development projects, against $4.07 per share in operating improvements. It is also investing in production facilities in Virginia and Texas.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.